NEW YORKThe first clinical trials of a live genetically
engineered Salmonella typhimurium bacterium are expected to
get underway in the second half of this year in patients with
cutaneous metastases of melanoma and breast cancer.
Terrence W. Doyle, PhD, vice president for research and development,
Vion Pharmaceuticals, Inc., New Haven, Connecticut, revealed plans
for the phase I study at Current Concepts in Cancer Therapy II, a
scientific symposium sponsored by Long Ridge Associates. Developed in
his companys proprietary program, Tumor Amplified Protein
Expression Therapy (TAPET), the bacterium, VNP20009, will be injected
directly into the skin lesions in the initial trial.
The aim of the study will be to determine the agents safety and
appropriate dose range in humans. Were looking for the
minimum effective inoculum, Dr. Doyle said. Unlike many
antitumor agents, because this is a multiplying vector, we dont
have any need to try to reach a maximum tolerated dose, and it is far
better to just simply find the dose where we can get uniform colonization.
Animal studies have shown that the bacteria preferentially target
tumors over normal tissue by more than 1000:1, Dr. Doyle said. An
important difference from other therapeutic modalities, he added, is
that the motile organism penetrates all compartments of the tumor,
including the hypoxic and necrotic layers.
In contrast to wild type salmonella, VNP20009 produced no septic
shock in swine and no changes in the body temperature of cynomologus
monkeys. Tests of antibiotic sensitivity showed that if
anything, it was more sensitive than the wild strain, Dr. Doyle commented.
Ultimately, Vion researchers expect TAPET to deliver recombinant
genes or other toxic payloads to solid tumor, but, in research,
VNP20009 alone achieved 95% suppression of B16 melanoma in mice, a
level slightly better than that seen with optimal doses of
fluorouracil and cyclophosphamide.
Human Colon Cancer Model
In a model of human colon carcinoma DLD-1 in mice, VNP20009 was
injected on day 17 after tumor implantation, when the median tumor
volume was 300 mm². With the agent, were able to
stop the tumor growth cold, Dr. Doyle said, whereas the
control animals progressed rather quickly to death.
In research leading up to clinical trials, B16 melanoma was implanted
into both flanks of mice. Five days later, B16 tumor cells were
injected into the tail vein causing implantation in the lungs.
Without treatment, the mice die at day 21 or 22 from growth of the
flank tumors. Injection of VNP20009 into one of these tumors
induces excellent inhibition of that tumor, Dr. Doyle said, and
a little less good inhibition of the contralateral tumor as
well as inhibition of the lung mets. When VNP20009 was injected
into the tail vein, both the laterally implanted tumors and the lung
mets were equally suppressed (see figure).
Based on these findings, the company hopes to move to a phase I study
of IV administration.